<DOC>
	<DOCNO>NCT00246064</DOCNO>
	<brief_summary>The purpose study evaluate ability maintenance dosage regimen infliximab achieve sustain least 40 % improvement baseline total joint count patient active Rheumatoid Arthritis ( RA ) methotrexate tapering .</brief_summary>
	<brief_title>The Infliximab Rheumatoid Arthritis Methotrexate Tapering ( iRAMT ) Protocol</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) chronic autoimmune disorder unknown etiology occur approximately one percent population . Current therapy RA comprise non-steroidal anti-inflammatory drug ( NSAIDs ) early stage disease , ultimately give way oral glucocorticoid disease-modifying anti-rheumatic drug ( DMARDs ) disease progressively worsen . Therapy DMARDs ( e.g. , D-penicillamine , auranofin , hydroxychloroquine , azathioprine , methotrexate ) ideal generally slow onset action ( measured month ) , variable level effectiveness , dose-limiting toxicity . Methotrexate ( MTX ) become DMARD choice many rheumatologist faster mode action well record prolong use . However , despite use high dos MTX , many patient experience partial relief symptom still feature active disease . The current product labeling provide range infliximab dos . Four fixed maintenance dose regimen prove safe efficacious Anti-TNF Trial Rheumatoid Arthritis Concomitant Therapy ( ATTRACT ) trial . However , efficacy incremental dose titration patient RA achieve maintain clinically important improvement baseline status establish clinical trial setting . Additionally , whether MTX taper possible patient achieve clinically important improvement baseline status demonstrate . The iRAMT trial utilizes prescribe strategy infliximab dose titration event individual achieve 40 % improvement combine swollen tender joint count , disease flare recurrent worsen . The iRAMT trial defines clinically important improvement least 40 % improvement baseline . Once 40 % improvement achieve , MTX taper initiated appropriate specific patient . The primary efficacy endpoint number ( % ) patient maintenance dose infliximab achieve least 40 % improvement baseline combine tender swollen joint count tolerate reduction MTX dose Week 54 . Hence , trial provide information regard infliximab dose titration strategy well MTX taper schedule patient respond therapy . The iRAMT trial examine , manner consistent clinical practice , schedule infliximab maintenance allow taper MTX occur . Patients receive Infliximab infusion minimum dose 3 mg/kg Weeks 0 , 2 , 6 every 8 week thereafter Week 46 . During study , dose infliximab may increase single 100-mg vial use specified regimen maximum 10 mg/kg every 4 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Previous diagnosis RA accord revised 1987 criterion American Rheumatism Association ( Arnett et al. , 1988 ) patient must minimum 8 tender 4 swollen joint disease diagnose least 3 month prior screen patient must use oral parenteral MTX least previous 3 month , stable dose 7.5 25 mg per week least previous 1 month woman childbearing potential must test negative pregnancy use adequate birth control measure patient must document purified protein derivative ( PPD ) skin test perform prescreening . Patients receive prior treatment infliximab therapeutic agent target reduce tumor necrosis factor ( TNF ) ( e.g. , etanercept , pentoxifylline thalidomide ) within previous 3 month patient incapacitated history infect joint prosthesis within previous 5 year patient concomitant diagnosis congestive heart failure ( CHF ) , history know malignancy within previous 5 year , case active latent tuberculosis ( TB ) , acute chronic serious infection within past 3 month know substance abuse ( drug alcohol ) within previous 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Infliximab infusion</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Remicade</keyword>
</DOC>